The Tyndall Effect: Why Under-Eye Filler Can Look Blue, and What Actually Fixes It

Of all the complications associated with under-eye filler, one of the most common is also one of the least understood by patients: a persistent bluish or grayish discoloration that appears days or weeks after treatment and does not go away. Patients often assume it is a bruise that will resolve. It is not. It is an optical phenomenon called the Tyndall effect, and understanding why it happens explains a great deal about why the tear trough is the most technique-sensitive filler site on the face.

The Tyndall effect is a principle from physics, not medicine. When light passes through a translucent medium containing suspended particles, shorter blue wavelengths scatter more than longer red wavelengths. It is the same reason the sky appears blue. Hyaluronic acid filler is a clear gel made of cross-linked particles suspended in solution. When a deposit of that gel sits too close to the surface of thin skin, incoming light scatters within it, and the blue wavelengths bounce back toward the observer. The result is a soft blue-gray cast over the filler, often visible as a linear or crescent-shaped shadow that tracks exactly where the product was placed.

Why the under-eye area is the highest-risk site. Skin thickness varies enormously across the face. Cheek skin can measure well over a millimeter. The skin of the lower eyelid is among the thinnest on the body, in some individuals under half a millimeter, with minimal subcutaneous fat beneath it. That leaves almost no tissue to conceal a superficially placed gel. A depth error that would be invisible in the cheek becomes glaringly visible under the eye. This is a matter of anatomy and optics, not product quality. Even well-regarded fillers will Tyndall if placed in the wrong plane.

Depth is the main variable, but product choice matters too. Experienced injectors typically place tear trough filler deep, on or just above the bone of the orbital rim, beneath the orbicularis oculi muscle. In that plane, the muscle and overlying tissue mask the gel. Superficial placement, meaning within or just under the dermis, is the classic setup for Tyndall. Product selection compounds the risk. Fillers with higher hyaluronic acid concentrations and stronger water-binding behavior tend to swell and remain as cohesive superficial deposits, increasing scatter. Softer, lower-concentration gels designed for thin-skin areas are more forgiving, though no product is immune if injected too shallow.

Volume and migration play supporting roles. Overfilling raises the odds that product ends up closer to the surface than intended, and repeated treatments layered over residual old filler can push newer material upward. Hyaluronic acid in the tear trough is also known to persist far longer than package labeling suggests, sometimes for years, because the area has low metabolic activity and little muscular movement to break the gel down. A Tyndall discoloration can therefore last as long as the filler does, which is why waiting it out is rarely a practical strategy.

How it is distinguished from other causes of dark circles. Not every blue tint under the eye is Tyndall. Prominent veins, thin skin over the orbicularis muscle, post-inflammatory pigmentation, and true structural hollowing can all read as darkness. A few clinical clues point toward filler as the culprit: the discoloration appeared after treatment, it sits exactly along the injection path, it is often accompanied by a subtle sausage-like fullness or puffiness, and stretching the skin makes the blue deposit more distinct rather than making it disappear. Some clinicians shine a light tangentially across the area, since Tyndall deposits scatter light in a characteristic way that pigment does not.

The fix is straightforward, which is one advantage of hyaluronic acid. The standard correction is an injection of hyaluronidase, an enzyme that breaks down hyaluronic acid within hours to days. Because the offending deposit is superficial and usually small, modest enzyme doses often resolve the discoloration in one or two sessions. Patients should know two things. First, hyaluronidase does not discriminate perfectly, so some intended correction may dissolve along with the misplaced product, and re-treatment, if desired, is generally delayed by at least two weeks. Second, allergic reactions to hyaluronidase are rare but documented, so it should be administered in a clinical setting by someone trained to manage them.

What patients can reasonably ask before treatment. Sensible questions include which plane the injector intends to use, which filler is planned and why it suits thin skin, whether conservative volumes with staged follow-up are the plan, and whether hyaluronidase is stocked on site. None of these questions guarantee an outcome, but an injector who answers them fluently is signaling familiarity with the anatomy that makes this area unforgiving.

The takeaway: Tyndall is not a mystery reaction or a sign of a bad batch. It is predictable physics meeting thin anatomy. It is largely preventable with deep placement, appropriate product, and restraint, and when it does occur, it is one of the few filler complications with a reliable and fast-acting remedy.

Related reading: The tired look: factors beyond the under-eye.